Healthcare
EKF Diagnostics Holdings plc(EKDHF)
Live Price
Offline$0.39
+12.42% today
1Y Change
+22.80%
Window
Jun 25, 2025 โ Jun 19, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +2.7%
- EPS Growth
- -65.9%
- Dividend Yield
- 0.0%
Coverage: 253 bars ยท Jun 25, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
EKF Diagnostics Holdings plc (EKDHF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $0.39 and up 22.8% across the available one-year price window (Jun 25, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of +2.7%, EPS growth of -65.9%, a dividend yield of 0.0%. What stands out right now is revenue +2.7%, EPS -65.9%, free cash flow -28.3% with operating margin 13.1% and ROIC 3.3%. Valuation already assumes a fairly strong business story at P/E 54.7 and price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EKDHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.7% vs +7.6% peer median
Operating Margin
Below sector median
+13.1% vs +19.4% peer median
P/E
Above sector median
54.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 24, 2026 with revenue ahead of estimates by 0.0%.
The operating picture looks softer than before
Revenue is at +2.7% and EPS is at -65.9%, with operating margin around 13.1%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 22, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 24, 2026 | +0.0% | +0.0% | +0.0% | -13.5% |
2025 Sep 16, 2025 | -14.0% | +0.0% | +0.0% | -5.6% |
2025 May 14, 2025 | โ | +0.0% | +7.1% | +10.2% |
Benchmark Edge
EKDHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EKDHF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EKDHF Max Drawdown
-30.63%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EKDHF and SPY.
Company Overview
EKF Diagnostics Holdings plc
Other OTC
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
- Leadership
- Gavin Joseph Jones
- IPO Date
- Nov 17, 2014
- Employees
- 303
- Street Address
- Avon House
- Mailing
- Cardiff, CF64 2EZ
- Region
- Cardiff, GB
- Reporting Currency
- USD
- Investor Line
- 44 29 2071 0570
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 54.7
- EV/EBITDA
- 7.9
- Price/Sales
- 2.2
- Price/Book
- 1.7
Growth
- Revenue
- +2.7%
- EPS
- -65.9%
- Free Cash Flow
- -28.3%
Profitability
- Gross Margin
- 51.4%
- Operating Margin
- 13.1%
- Net Margin
- 4.1%
- ROE
- 3.0%
- ROIC
- 3.3%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 4.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.